How to buy NantKwest stock | $37.3

NantKwest Inc is a biotechnology business based in the US. NantKwest shares (NK) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 171 staff and has a trailing 12-month revenue of around 0.00.

NantKwest stock price (NASDAQ: NK)

Use our graph to track the performance of NK stocks over time.

NantKwest shares at a glance

• Key figures

Information last updated 2021-09-26.

Latest market close	$37.30
52-week range	$6.80 - $46.82
50-day moving average	$28.70
200-day moving average	$14.19
Wall St. target price	$18.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.89

Buy NantKwest shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NantKwest stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NantKwest price performance over time

Historical closes compared with the close of $37.3 from 2021-10-15

1 week (2021-10-08)	-2.36%
1 month (2021-09-17)	-2.86%
3 months (2021-07-16)	-1.37%
6 months (2021-04-16)	-17.73%

1 year (2020-10-16)	304.56%
2 years (2019-10-17)	2,982.64%
3 years (2018-10-17)	1,192.89%
5 years (2016-10-17)	498.72%

Is NantKwest under- or over-valued?

Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NantKwest's PEG ratio

NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NantKwest financials

Revenue TTM	$111,000
Gross profit TTM	$111,000
Return on assets TTM	-36.2%
Return on equity TTM	-77.61%
Profit margin	0%
Book value	$1.08
Market capitalisation	$3.6 billion

TTM: trailing 12 months

Shorting NantKwest shares

There are currently 3.9 million NantKwest shares held short by investors – that's known as NantKwest's "short interest". This figure is 27.9% down from 5.4 million last month.

There are a few different ways that this level of interest in shorting NantKwest shares can be evaluated.

NantKwest's "short interest ratio" (SIR)

NantKwest's "short interest ratio" (SIR) is the quantity of NantKwest shares currently shorted divided by the average quantity of NantKwest shares traded daily (recently around 1.1 million). NantKwest's SIR currently stands at 3.71. In other words for every 100,000 NantKwest shares traded daily on the market, roughly 3710 shares are currently held short.

However NantKwest's short interest can also be evaluated against the total number of NantKwest shares, or, against the total number of tradable NantKwest shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NantKwest's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NantKwest shares in existence, roughly 50 shares are currently held short) or 0.1547% of the tradable shares (for every 100,000 tradable NantKwest shares, roughly 155 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NantKwest.

Find out more about how you can short NantKwest stock.

NantKwest share dividends

We're not expecting NantKwest to pay a dividend over the next 12 months.

Have NantKwest's shares ever split?

NantKwest's shares were split on a 8:1 basis on 16 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.

NantKwest share price volatility

Over the last 12 months, NantKwest's shares have ranged in value from as little as $6.8 up to $46.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.3862. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NantKwest overview

NantKwest, Inc. , a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc.

Frequently asked questions

What percentage of NantKwest is owned by insiders or institutions?
Currently 67.978% of NantKwest shares are held by insiders and 9.779% by institutions. How many people work for NantKwest?
Latest data suggests 171 work at NantKwest. When does the fiscal year end for NantKwest?
NantKwest's fiscal year ends in December. Where is NantKwest based?
NantKwest's address is: 3530 John Hopkins Court, San Diego, CA, United States, 92121 What is NantKwest's ISIN number?
NantKwest's international securities identification number is: US45256X1037 What is NantKwest's CUSIP number?
NantKwest's Committee on Uniform Securities Identification Procedures number is: 63016Q102